Activity estimation in radioimmunotherapy using magnetic nanoparticles
Authors:
Open Access
- 1 April 2015
- journal article
- Vol. 27 (2) , 203-208
Abstract
Estimation of activity accumulated in tumor and organs is very important in predicting the response of radiopharmaceuticals treatment. In this study, we synthesized 177Lutetium (177Lu)-trastuzumab-iron oxide nanoparticles as a double radiopharmaceutical agent for treatment and better estimation of organ activity in a new way by magnetic resonance imaging (MRI). 177Lu-trastuzumab-iron oxide nanoparticles were synthesized and all the quality control tests such as labeling yield, nanoparticle size determination, stability in buffer and blood serum up to 4 d, immunoreactivity and biodistribution in normal mice were determined. In mice bearing breast tumor, liver and tumor activities were calculated with three methods: single photon emission computed tomography (SPECT), MRI and organ extraction, which were compared with each other. The good results of quality control tests (labeling yield: 61%±2%, mean nanoparticle hydrodynamic size: 41±15 nm, stability in buffer: 86%±5%, stability in blood serum: 80%±3%, immunoreactivity: 80%±2%) indicated that 177Lu-trastuzumab-iron oxide nanoparticles could be used as a double radiopharmaceutical agent in mice bearing tumor. Results showed that 177Lu-trastuzumab-iron oxide nanoparticles with MRI had the ability to measure organ activities more accurate than SPECT. Co-conjugating radiopharmaceutical to MRI contrast agents such as iron oxide nanoparticles may be a good way for better dosimetry in nuclear medicine treatment.Keywords
This publication has 22 references indexed in Scilit:
- Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab RadioimmunotherapyJournal of Nuclear Medicine, 2014
- Radioimmunotherapy with α-Particle-Emitting RadionuclidesImmunotherapy, 2014
- Radioimmunotherapy with 131I-Rituximab in a Patient with Diffuse Large B-Cell Lymphoma Relapsed After Treatment with 90Y-Ibritumomab TiuxetanNuclear Medicine and Molecular Imaging, 2013
- 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpointBritish Journal of Cancer, 2013
- In vitro and in vivo analysis of [64Cu-NO2A-8-Aoc-BBN(7–14)NH2]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumorsNuclear Medicine and Biology, 2009
- OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.2005
- MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agentsMagnetic Resonance Imaging, 2004
- Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.2003
- Voxeldose: A Computer Program for 3-D Dose Calculation in Therapeutic Nuclear MedicineCancer Biotherapy and Radiopharmaceuticals, 2003
- Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excessJournal of Immunological Methods, 1984